Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Diana Bello RoufaiA GonçalvesT De La Motte RougeS AklaC BlonzJ GrenierJ GligorovM SaghatchianC BailleuxH SimonI DesmoulinsZ TharinE RenaudM BerthoM-A BenderraSuzette DelalogeL RobertP CottuJ Y PiergaD LoiratA BertucciB RenoufFrancois-Clement BidardF LereboursPublished in: Oncogene (2023)